FDA Approved: DAYBUE — Supplemental Application (Acadia Pharmaceuticals Inc.)

View source ↗

Summary

FDA is reviewing a supplemental application for Daybue (trofinetide) from Acadia Pharmaceuticals under NDA 217026, related to Rett syndrome treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rett Syndrome

Drugs mentioned

• DAYBUE (trofinetide)

Snippet

SUPPL AP for DAYBUE (TROFINETIDE)